Absci Corp at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Dave Praharaj - JP Morgan - Analyst : I'll kick things off. So you've advanced your AI platform over the last couple of years quite impressively. Do you see room for even further progress? And what does that look like? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 16, 2025 / 12:30AM, ABSI.OQ - Absci Corp at JPMorgan Healthcare Conference

Question: Dave Praharaj - JP Morgan - Analyst : And I guess taking a step back, what are some of the key differentiating features and capabilities that your platform has that set it apart from your competitors and enables your drug creation pipeline? Unidentified Company Representative I think Sean is going to let me take one. So I think you saw some of it here today. We are, in my mind, and I used to be an investor in this space, we're clearly the leader in de novo design. So we're now taking these models, and we're designing against targets that you can't address in any other way. I think the HIV case study is a great example of that. But we've done other work with partners against ion channels and very difficult epitopes and transmembrane proteins that we can't share publicly where we've seen success, and we've seen success in a rapid amount of time. In one of those partnerships, we designed against a difficult target de novo. In six months, we delivered leads. So we're starting to see the ability to attack these targets that have fundamentally solid biology that can treat diseases where no one else has been able to drug them. And I think that opens up a whole new area of therapeutics that don't exist today. And then on the other side of that, with some of our lead optimization models, you saw Sean talk about designing in pharmacology. And that's a direction that we've -- we started taking early this past year, and you're seeing the results here. Now we're generating pH dependency in our molecules, if that's something we want to engineer into a TPP. So that flexibility to design in pharmacology is also a key way to deliver differentiation and ultimately, to deliver what patients need.